Gene therapies and LRRK2 inhibition are at the forefront of prescribers’ interest, highlighting the need for a truly disease modifying
Despite Vabysmo’s gains in 2023, Eylea HD will prove to be a formidable force in the coming year. [Exton PA,
According to Spherix Global Insights, US nephrologists have expressed a high level of enthusiasm for Novartis’ iptacopan and atrasentan, as
With competition finally hitting the US market, branded adalimumab (Humira) is finally losing market share, according to the third quarter update of
In both the U.S. and Europe, clinicians want to limit treatment with glucocorticoids — steroid hormones whose long-term use for
Oral drugs have raced to the front of the pack in the crowded migraine therapy space and appear to be
Despite overall biologic growth in both geographies, use of advanced systemic treatments in the US outpaces the EU5. EXTON, PA.,
Analysis of 1,025 recently switched PsA patients reveals second- or later-line usage of IL-17, IL-23, and JAK inhibitors growing in
[Exton PA, September 26, 2023] — Spherix Global Insights, a trusted leader in pharmaceutical market research, is delighted to announce
Spherix Global Insights, a leading provider of market research, conducted a survey using a sample of 81 rheumatologists, 83 gastroenterologists,
Pharmaceutical industry veteran Dan Barton to serve as Chief Executive Officer. Exton PA, September 21, 2023 — Spherix Global Insights,
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber
